Form 4: Hims & Hers CFO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc. Chief Financial Officer, Oluyemi Okupe, reported the sale of 7,163 shares of Class A Common Stock for an average price of $36.4863, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported a transaction on July 6, 2026.
• This transaction involved the exercise of stock options and the subsequent sale of 7,163 shares of Class A Common Stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on May 21, 2025.
• The average selling price for these shares was $36.4863, with individual sales occurring between $36.35 and $36.70.
• Following these transactions, Okupe beneficially owns 284,321 shares directly and 7,853 shares indirectly through a trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the CFO selling shares, even though it was executed under a pre-planned 10b5-1 trading strategy. This can sometimes be interpreted as a lack of insider confidence.

Negatives

• The Chief Financial Officer sold a significant number of shares (7,163) which could be perceived negatively by the market, despite being executed under a pre-planned trading strategy.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by the market as a lack of confidence in the company's near-term prospects, potentially impacting share price.
• The Rule 10b5-1 plan itself, while designed to avoid insider trading concerns, is subject to scrutiny and its adoption date (May 21, 2025) is noted.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance. It solely reports on a past transaction by an executive.

Management Comments

• The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
• Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $36.35 - $36.70.
• The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that executive stock sales, even under Rule 10b5-1 plans, are closely watched by investors in the telehealth and wellness sector. Such transactions can influence market sentiment and perceptions of insider confidence.

Stakeholder Impact

• Shareholders: May view the CFO's sale as a negative signal, potentially impacting share price, despite the transaction being part of a pre-arranged plan.
• Employees: May also interpret the sale as a sign of reduced confidence from leadership.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The Reporting Person has undertaken to provide full information regarding the number of shares sold at each separate price upon request.

Key Dates

Recommendation

The filing reports an insider sale under a Rule 10b5-1 plan, which is a standard practice. While insider sales can be a negative signal, the pre-planned nature mitigates concerns about immediate negative sentiment. Without further financial performance data or strategic updates, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

Hims & Hers Health, HIMS, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Share Sale, Chief Financial Officer, Oluyemi Okupe, SEC Filing